Alterity Therapeutics Ltd ADR ATHE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Trading Information
- Previous Close Price
- $2.44
- Day Range
- $2.17–2.58
- 52-Week Range
- $2.01–5.89
- Bid/Ask
- $2.28 / $2.58
- Shares Outstanding
- 19.09M
- Market Cap
- $42.38M
- Volume/Avg
- 40,341 / 84,297
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 11
Valuation
Metric | ATHE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.63 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ATHE |
|---|---|
Quick Ratio | 14.26 |
Current Ratio | 14.52 |
Interest Coverage | — |
Quick Ratio
ATHE
Profitability
Metric | ATHE |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATHE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|?^L@bH& | LOCK|N^GH | $138B | |||
| Moderna Inc MRNA | LOCK|D?qQQx | LOCK|<#M | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|q<K@x? | LOCK|xxj$t | $93B | |||
| argenx SE ADR ARGX | LOCK|skKql? | LOCK|RS | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|C#%V@# | LOCK|jfw | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|m<fvzTjJ | LOCK|wRZ$v | $30B | |||
| Incyte Corp INCY | LOCK|Bqd!F^ | LOCK|b@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|b$@!x<% | LOCK|Sc | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|h%H$V# | LOCK|wmC@S | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|?ms$M%% | LOCK|lt | $15B |
United States